Patents by Inventor Yoo-Na LEE

Yoo-Na LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF
    Publication number: 20220242910
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Application
    Filed: January 19, 2022
    Publication date: August 4, 2022
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ
  • Agonist of spexin-based galanin type 2 receptor and use thereof
    Patent number: 11248023
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 15, 2022
    Assignee: Neuracle Science Co., Ltd
    Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
  • AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF
    Publication number: 20200010509
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Application
    Filed: July 15, 2019
    Publication date: January 9, 2020
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ
  • Agonist of spexin-based galanin type 2 receptor and use thereof
    Patent number: 10385098
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 20, 2019
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
  • AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF
    Publication number: 20180319841
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Application
    Filed: November 30, 2016
    Publication date: November 8, 2018
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ